OctoPlus Proves Efficacy of OP-145 in Phase II Ear Infection Study

LEIDEN, NETHERLANDS--(Marketwire - July 28, 2008) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that efficacy of OP-145, a novel therapy for the treatment of chronic middle ear infection (otitis media), was demonstrated in an interim analysis of the Phase II study. As a result, OctoPlus will close the study because its goal has been achieved.
MORE ON THIS TOPIC